Additional Tables

Extra Table 1 Outcomes of cervical cancer patients according to clinical features and arm of treatment

Features of patient	Persistence/Progression			Recurrence		
	Arm A	Arm B	p-value	Arm A	Arm B	p-value
	n=17	n=30		n=22	n=16	
Age						
≤ 40 years, n=43	2 (4.7)	4 (9.3)	0.564	2 (4.7)	6 (13.9)	0.226
> 40 years, n=216	15 (6.9)	26 (12.0)	0.143	20 (9.3)	10 (4.6)	0.091
Histology						
SCC, n=198	13 (6.7)	23 (11.6)	0.076	15 (7.6)	8 (4.0)	0.129
ACA/AS, n=61	4 (6.6)	7 (11.5)	0.289	7 (11.5)	8 (13.1)	0.510
FIGO 2018 stage						
IIB, n=131	6 (4.6)	12 (9.2)	0.200	5 (3.8)	7 (5.3)	0.680
IIIA, n=3	1 (33.3)	-	-	1 (33.3)	-	-
IIIB, n=60	5 (8.3)	5 (8.3)	0.558	5 (8.3)	5 (8.3)	0.338
IIIC1r, n=62	5 (8.1)	11 (17.7)	0.149	11 (17.7)	4 (6.5)	0.018
IVA, n=3	-	2 (66.7)		-	-	
Tumor size						
≤ 4 cm, n=96	4 (4.2)	9 (9.4)	0.158	5 (5.2)	5 (5.2)	0.944
> 4 cm, n=163	13 (8.0)	21 (12.9)	0.114	17 (10.4)	11 (6.7)	0.323
Total radiation dose						
<85 Gy, n=23	4 (17.4)	9 (39.1)	0.645	-	1 (4.3)	0.455
≥85 Gy, n=236	13 (9.6)	21 (8.9)	0.100	22 (9.3)	15 (6.4)	0.327
Total treatment times						
≤ 56 days, n=123	7 (5.7)	15 (12.2)	0.094	9 (7.3)	8 (6.5)	0.822
>56 Days, n=136	10 (7.4)	15 (11.0)	0.325	13 (9.6)	8 (5.9)	0.297
Cisplatin cycle						
<5 cycles, n=67	10 (14.9)	10 (14.9)	0.811	3 (4.5)	1 (1.5)	0.347
≥ 5 cycles, n=192	7 (3.6)	20 (3.6)	0.216	19 (9.9)	15 (7.8)	0.486
Cisplatin total dose						
<200 mg, n=52	7 (13.5)	11 (21.2)	0.573	1 (1.9)	3 (5.8)	0.420
≥200 mg, n=207	10 (4.8)	19 (9.2)	0.062	21 (10.1)	13 (5.3)	0.254

Extra Table 2 Sites of treatment failure according to clinical features of cervical cancer and treatment

Features	Total	No	Persistence	Progression	Recurrence
			Yes		
Histology					
SCC	198	139 (70.2)	21 (10.6)	15 (7.6)	23 (11.6)
ACA/ AS	61	35 (57.4)	10 (16.4)	1 (1.6)	15 (24.6)
Age group					
≤ 40 years	43	29 (67.4)	4 (9.3)	2 (4.7)	8 (18.6)
> 40 years	216	145 (67.1)	27 (12.5)	14 (6.5)	30 (13.9)
FIGO 2018 stage					
IIB	131	101 (77.1)	11 (8.4)	7 (5.3)	12 (9.2)
IIIA	3	1 (33.3)	-	1 (33.3)	1 (33.3)
IIIB	60	40 (66.7)	8 (13.3)	2 (3.3)	10 (16.7)
IIIC1r	62	31 (50)	11 (17.7)	5 (8.1)	15 (24.2)
IVA	3	1 (33.3)	1 (33.3)	1 (33.3)	-
Tumor size					
≤ 4 cm.	96	73 (76)	7 (7.3)	6 (6.3)	10 (10.4)
> 4 cm.	163	101 (62)	24 (14.7)	10 (6.1)	28 (17.2)
Total radiation dose					
<85 Gy	23	9 (39.1)	10 (43.5)	3 (13)	1 (4.3)
≥85 Gy	236	165 (69.9)	21 (8.9)	13 (5.5)	37 (15.7)
Total treatment times					
≤ 56 days	123	84 (68.3)	16 (13)	6 (4.9)	17 (13.8)
>56 Days	136	90 (66.2)	15 (11)	10 (7.4)	21 (15.4)
Cisplatin cycle					
<5 cycles	67	43 (64.2)	16 (23.9)	4 (6)	4 (6)
≥ 5 cycles	192	131 (68.2)	15 (7.8)	12 (6.3)	34 (17.7)
Cisplatin total dose					
<200 mg	52	30 (57.7)	15 (28.8)	3 (5.8)	4 (7.7)
≥200 mg	207	144 (69.6)	16 (7.7)	13 (6.3)	34 (16.4)

Extra Table 3 Sites of treatment failure according to clinical features of cervical cancer and treatment

Features	Total	Treatment failure		
		Loco-regional	Systemic	Loco-regional and systemic
Age group				
≤ 40 years	14	6 (42.9)	5 (35.7)	3 (21.4)
> 40 years	71	39 (54.9)	21 (29.6)	11 (15.5)
FIGO 2018 stage				
IIB	30	14 (46.7)	12 (40)	4 (13.3)
IIIA	2	1 (50)	1 (50)	-
IIIB	20	10 (50)	4 (20)	6 (30)
IIIC1r	31	19 (61.3)	9 (29)	3 (9.7)
IVA	2	1 (50)	-	1 (50)
Histology				
SCC	59	33 (55.9)	17 (28.8)	9 (15.3)
ACA/ AS	26	12 (46.2)	9 (34.6)	5 (19.2)
Tumor size				
≤ 4 cm.	23	13 (56.5)	7 (30.4)	3 (13)
> 4 cm.	62	32 (51.6)	19 (30.6)	11 (17.7)
Total radiation dose				
Total dose <85 Gy	14	12 (85.7)	-	2 (14.3)
Total dose ≥85 Gy	71	33 (46.5)	26 (36.6)	12 (16.9)
Total treatment times				
≤ 56 days	39	22 (56.4)	10 (25.6)	7 (17.9)
>56 Days	46	23 (50)	16 (34.8)	7 (15.2)
Brachytherapy techniques				
2D Planning	63	31 (49.2)	22 (34.9)	10 (15.9)
3D Planning	22	14 (63.6)	4 (18.2)	4 (18.2)
Cisplatin cycle				
<5 cycles	24	18 (75)	3 (12.5)	3 (12.5)
≥ 5 cycles	61	27 (44.3)	23 (37.7)	11 (18)
Cisplatin total dose				
<200 mg	22	18 (81.8)	2 (9.1)	2 (9.1)
≥200 mg	63	27 (42.9)	24 (38.1)	12 (19)

Extra Table 4 Sites of treatment failure according to clinical features of cervical cancer and arm of treatment

Features of patient	LR (n=45)			Systemic (n=26)			Systemic and local (n=14)		
	Arm A	Arm B	p-value	Arm A	Arm B	p-value	Arm A	Arm B	p-value
	n=17	n=28		n=17	n=9		n=5	n=9	
Age									
≤ 40 years, n=43	2 (4.7)	4 (9.3)	0.564	2 (4.7)	3 (7.0)	0.841	-	3 (7.0)	0.110
> 40 years, n=216	15 (6.9)	24 (11.1)	0.098	15 (6.9)	6 (2.8)	0.043	5 (2.3)	6 (2.8)	0.372
Histology									
SCC, n=198	13 (6.6)	20 (10.1)	0.204	11 (5.6)	6 (3.0)	0.190	4 (2.0)	5 (2.5)	0.756
ACA/AS, n=61	4 (6.6)	8 (13.1)	0.176	6 (9.8)	3 (4.9)	0.303	1 (1.6)	4 (6.6)	0.150
FIGO 2018 stage									
IIB, n=131	5 (3.8)	9 (6.9)	0.357	5 (3.8)	7 (5.3)	0.680	1 (0.8)	3 (2.3)	0.364
IIIA, n=3	1 (33.3)	-	-	1 (33.3)	-	-	-	-	-
IIIB, n=60	4 (6.7)	6 (10.0)	0.198	3 (5.0)	1 (1.7)	0.484	3 (5.0)	3 (5.0)	0.663
IIIC1r, n=62	7 (11.3)	12 (19.4)	0.297	8 (12.9)	1 (1.6)	0.639	1 (1.6)	2 (3.2)	0.632
IVA, n=3	-	1 (33.3)	-	-	-	-	-	1 (33.3)	-
Tumor size									
≤ 4 cm, n=96	5 (5.2)	8 (8.3)	0.416	4 (4.2)	3 (3.1)	0.653	-	3 (3.1)	0.085
> 4 cm, n=163	12 (7.4)	20 (12.3)	0.106	13 (8.0)	6 (3.7)	0.093	5 (3.1)	6 (3.7)	0.739
Total radiation dose									
<85 Gy, n=23	4 (17.4)	8 (34.8)	0.879	-	-	-	-	2 (8.7)	0.280
≥85 Gy, n=236	13 (5.5)	20 (8.5)	0.141	17 (7.2)	9 (3.8)	0.127	5 (2.1)	7 (3.0)	0.494
Total treatment times									
≤ 56 days, n=123	7 (5.7)	15 (12.2)	0.217	6 (4.9)	4 (3.3)	0.527	3 (2.4)	4 (3.3)	0.681
>56 Days, n=136	10 (7.4)	13 (9.6)	0.376	11 (8.1)	5 (3.7)	0.063	2 (1.5)	5 (3.7)	0.218
Cisplatin cycle									
<5 cycles, n=67	8 (11.9)	10 (14.9)	0.439	3 (4.5)	-	0.262	2 (3.0)	1 (1.5)	0.609
≥ 5 cycles, n=192	9 (4.7)	18 (9.4)	0.191	14 (7.3)	9 (4.7)	0.223	3 (1.6)	8 (4.2)	0.138
Cisplatin total dose									
<200 mg, n=52	6 (11.5)	12 (23.1)	0.250	1 (1.9)	1 (1.9)	0.867	1 (1.9)	1 (1.9)	0.867
≥200 mg, n=207	11 (5.3)	16 (7.7)	0.243	16 (7.7)	8 (3.9)	0.107	4 (1.9)	8 (3.9)	0.202
Brachytherapy techniques									
2D Planning, n=171	12 (7.0)	19 (11.1)	0.154	13 (7.6)	9 (5.3)	0.377	2 (1.7)	8 (4.7)	0.061
3D Planning, n=88	5 (5.7)	9 (10.2)	0.283	4 (4.5)	-	0.064	3 (3.4)	1 (1.1)	0.284

% of events in all patients in each arm